Rani Therapeutics Holdings logo
RANI logo

Rani Therapeutics HoldingsNasdaqGM:RANI Stock Report

Market Cap US$94.8m
Share Price
n/a
1Y-59.9%
7D9.4%
Portfolio Value
View

Rani Therapeutics Holdings, Inc.

NasdaqGM:RANI Stock Report

Market Cap: US$94.8m

RANI Stock Overview

Operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. More details

RANI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Rani Therapeutics Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Rani Therapeutics Holdings
Historical stock prices
Current Share PriceUS$1.52
52 Week HighUS$8.75
52 Week LowUS$1.24
Beta0.16
1 Month Change11.76%
3 Month Change-36.93%
1 Year Change-59.89%
3 Year Change-90.79%
5 Year Changen/a
Change since IPO-86.18%

Recent News & Updates

Is Rani Therapeutics Holdings (NASDAQ:RANI) Using Too Much Debt?

Feb 07
Is Rani Therapeutics Holdings (NASDAQ:RANI) Using Too Much Debt?

Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?

Jul 16
Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?

Recent updates

Is Rani Therapeutics Holdings (NASDAQ:RANI) Using Too Much Debt?

Feb 07
Is Rani Therapeutics Holdings (NASDAQ:RANI) Using Too Much Debt?

Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?

Jul 16
Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?

Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?

Mar 20
Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?

Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development

Aug 08

We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate

Feb 13
We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate

Shareholder Returns

RANIUS PharmaceuticalsUS Market
7D9.4%0.2%0.2%
1Y-59.9%1.3%22.0%

Return vs Industry: RANI underperformed the US Pharmaceuticals industry which returned 1.3% over the past year.

Return vs Market: RANI underperformed the US Market which returned 22% over the past year.

Price Volatility

Is RANI's price volatile compared to industry and market?
RANI volatility
RANI Average Weekly Movement10.4%
Pharmaceuticals Industry Average Movement10.5%
Market Average Movement6.1%
10% most volatile stocks in US Market18.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: RANI has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: RANI's weekly volatility has decreased from 16% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012140Talat Imranwww.ranitherapeutics.com

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions.

Rani Therapeutics Holdings, Inc. Fundamentals Summary

How do Rani Therapeutics Holdings's earnings and revenue compare to its market cap?
RANI fundamental statistics
Market capUS$94.76m
Earnings (TTM)-US$28.17m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RANI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$28.17m
Earnings-US$28.17m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.85
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio490.1%

How did RANI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 01:52
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rani Therapeutics Holdings, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Julian HarrisonBTIG
Edward NashCanaccord Genuity